SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors
Authors:
- 10 September 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 222 (12) , 1974-1984
Abstract
Background: Convalescent plasma therapy is a leading treatment for conferring temporary immunity to COVID-19–susceptible individuals or for use as post-exposure prophylaxis. However, not all recovered patients develop adequate antibody titers for donation and the relationship between avidity and neutralizing titers is currently not well understood. Methods: SARS-CoV-2 anti-spike and anti-nucleocapsid IgG titers and avidity were measured in a longitudinal cohort of COVID-19 hospitalized patients (n = 16 individuals) and a cross-sectional sample of convalescent plasma donors (n = 130). Epidemiologic correlates of avidity were examined in donors by linear regression. The association of avidity and a high neutralizing titer (NT) were also assessed in donors using modified Poisson regression. Results: Antibody avidity increased over duration of infection and remained elevated. In convalescent plasma donors, higher levels of anti-spike avidity were associated with older age, male sex, and hospitalization. Higher NTs had a stronger positive correlation with anti-spike IgG avidity (Spearman ρ = 0.386; P < .001) than with anti-nucleocapsid IgG avidity (Spearman ρ = 0.211; P = .026). Increasing levels of anti-spike IgG avidity were associated with high NT (≥160) (adjusted prevalence ratio = 1.58 [95% confidence interval = 1.19–2.12]), independent of age, sex, and hospitalization. Conclusions: SARS-CoV-2 antibody avidity correlated with duration of infection and higher neutralizing titers, suggesting a potential alternative screening parameter for identifying optimal convalescent plasma donors.Keywords
Funding Information
- Division of Intramural Research
- National Institute of Allergy and Infectious Diseases (R01AI120938, R01AI120938S1, R01AI128779)
- National Institutes of Health (UM1-AI068613, R01-095068, AI052733, AI15207, HL059842)
- Center of Excellence in Influenza Research and Surveillance (HHSN272201400007C, T32AI102623)
- National Heart, Lung, and Blood Institute (K23HL151826)
- Bloomberg Philanthropies
This publication has 27 references indexed in Scilit:
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and ImmunityMicrobiology and Molecular Biology Reviews, 2016
- Serological assays for emerging coronaviruses: Challenges and pitfallsVirus Research, 2014
- Neutralization of Virus Infectivity by Antibodies: Old Problems in New PerspectivesAdvances in Biology, 2014
- An immunosuppressed Syrian golden hamster model for SARS-CoV infectionVirology, 2008
- Use of Antibody Avidity Assays for Diagnosis of Severe Acute Respiratory Syndrome Coronavirus InfectionClinical and Vaccine Immunology, 2007
- Human Immunodeficiency Virus (HIV) Antibody Avidity Testing To Identify Recent Infection in Newly Diagnosed HIV Type 1 (HIV-1)-Seropositive Persons Infected with Diverse HIV-1 SubtypesJournal of Clinical Microbiology, 2007
- Use of Immunoglobulin G Avidity Assays for Differentiation of Primary from Previous Infections with West Nile VirusJournal of Clinical Microbiology, 2005
- Antibody Avidity Maturation during Severe Acute Respiratory Syndrome–Associated Coronavirus InfectionThe Journal of Infectious Diseases, 2005
- Epstein-Barr Virus (EBV) DNA in Sera of Patients with Primary EBV InfectionJournal of Clinical Microbiology, 2001